The Hindu Businessline

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

Under the deal, Dizal is eligible to receive $600 million upfront and up to $900 million more based on clinical and sales milestones

14 Jul 2026 1:14 pm